Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Boosted by Privium Fund Management B.V.

Privium Fund Management B.V. boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 81.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 20,607 shares of the biopharmaceutical company’s stock after purchasing an additional 9,235 shares during the period. Alnylam Pharmaceuticals makes up about 1.0% of Privium Fund Management B.V.’s holdings, making the stock its 23rd biggest holding. Privium Fund Management B.V.’s holdings in Alnylam Pharmaceuticals were worth $5,085,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Alta Advisers Ltd bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $252,000. Pekin Hardy Strauss Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $326,000. Principle Wealth Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $299,000. Kestra Advisory Services LLC raised its holdings in Alnylam Pharmaceuticals by 158.0% in the 3rd quarter. Kestra Advisory Services LLC now owns 6,994 shares of the biopharmaceutical company’s stock worth $1,726,000 after acquiring an additional 4,283 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in Alnylam Pharmaceuticals by 1.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,930 shares of the biopharmaceutical company’s stock worth $2,450,000 after acquiring an additional 115 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded down $0.72 on Friday, reaching $155.94. The stock had a trading volume of 2,829,678 shares, compared to its average volume of 2,343,089. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. Alnylam Pharmaceuticals, Inc. has a 1 year low of $154.30 and a 1 year high of $479.79. The stock has a market cap of $20.89 billion, a P/E ratio of 8.10 and a beta of 0.42. The company has a 50 day simple moving average of $228.57 and a 200 day simple moving average of $281.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the prior year, the business earned $2.90 earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on ALNY. Royal Bank Of Canada cut their target price on Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating on the stock in a research note on Friday, October 30th. Zacks Research cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Weiss Ratings restated a “hold (c)” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 29th. Stifel Nicolaus downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price target on the stock. in a report on Thursday, October 29th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $290.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $305.86.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach.

Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.